BTIG Initiates Coverage On Viridian Therapeutics with Buy Rating, Announces Price Target of $46
Portfolio Pulse from richadhand@benzinga.com
BTIG analyst Julian Harrison initiates coverage on Viridian Therapeutics (NASDAQ:VRDN) with a Buy rating and announces a price target of $46.
June 14, 2023 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viridian Therapeutics (NASDAQ:VRDN) receives a Buy rating and a $46 price target from BTIG analyst Julian Harrison.
The Buy rating and price target of $46 announced by BTIG analyst Julian Harrison for Viridian Therapeutics (NASDAQ:VRDN) indicate a positive outlook for the stock. This news is likely to attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100